Publication at First Faculty of Medicine |
2021
Abstract
Targeted therapy and immunotherapy have improved survival outcomes for patients with metastatic renal cell carcinoma. ESMO, NCCN and Czech society for oncology provide some guidelines for the most appropriate first-, secondand third-line treatment.
With the growing number of available therapeutic agents and improved survival, the optimal treatment patterns in fourth-line therapy need to be examined. No robust evidence exists to optimize treatment selection in this setting.
The fourth-line therapy varies significantly amongst different centers and jurisdictions.